The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists | 40 min
The role of the Pathologist is crucial in the emerging field of neoadjuvant therapy in melanoma. Understanding that their role is fundamental to patient...
Diagnosis and management of uveal melanoma | 44 min
Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic...
Refining pathological response assessment in neoadjuvant therapy for melanoma | 40 min
In this presentation, Pathologist Prof Richard Scolyer AO discusses how neoadjuvant therapy is transforming melanoma patient care. He also answers key questions around neoadjuvant-treated...
The future of melanoma and surgical oncology | 52 min
This presentation was recorded at A/Prof Alexander van Akkooi’s inaugural Australian lecture where he discusses his vision and aims for the future of melanoma...
Critical questions for a melanoma pathologist | 36 min
The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...
Toxicity management in melanoma | 45 min
Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...
Update on the adjuvant treatment of melanoma in 2021 | 13 min
In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...
Staging melanoma and bulky palpable Stage III melanoma – is surgery necessary? | 10 min
In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....
Management of in-transit melanoma in the time of active systemic therapy | 11 min
With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...